Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 39 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Terpos, Evangelos [Clear All Filters]
(2014).
Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index..
Ann Hepatol. 12(5), 749-57.
(2013). Helicobacter pylori infection in patients with nonalcoholic fatty liver disease..
Metabolism. 62(1), 121-6.
(2013). A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study..
Biomarkers. 18(7), 607-13.
(2013). Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid..
Endokrynol Pol. 63(4), 312-5.
(2012). Is serum IL-17A a useful systemic biomarker in patients with Langerhans cell histiocytosis?.
Mol Ther. 20(1), 6-7.
(2012). Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis..
J Clin Endocrinol Metab. 97(4), E618-21.
(2012). Dual-energy X-ray absorptiometry and quantitative ultrasound in patients with Paget's disease of bone before and after treatment with zoledronic acid: association with serum bone markers and Dickkopf-1..
J Clin Densitom. 13(2), 190-6.
(2010). The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis..
Clin Endocrinol (Oxf). 72(6), 752-7.
(2010). Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease..
J Bone Miner Metab. 28(6), 706-12.
(2010). Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid..
J Bone Miner Metab. 28(3), 314-9.
(2010). Paget's disease of bone: emphasis on treatment with zoledronic acid..
Expert Rev Endocrinol Metab. 4(5), 423-434.
(2009). RANKL inhibition for the management of patients with benign metabolic bone disorders..
Expert Opin Investig Drugs. 18(8), 1085-102.
(2009). Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid..
Support Care Cancer. 17(10), 1329-30.
(2009).